Studies Opened Since 2/5/16

Melanoma
16-18569 Other: National EA6141
Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Stages: III, IV  CT.GOV ID: NCT02339571
Primary Investigator: Elizabeth Gaughan
CRC: Emily Allred

Pediatric Oncology
16-17588 UVA multi-site UVA-GEN001
A Randomized, Placebo-Controlled Pilot Study of Genistein Supplementation in Pediatric Cancer Patients Receiving Myelosuppressive Chemotherapy
Stages: Any/all stages  CT.GOV ID: NCT02624388
Primary Investigator: William Petersen MD
CRC: Jessica Pritchard

Thoracic Oncology
16-18368 Non-UVA LUN13-175
Phase I/II study of carboplatin/nab-paclitaxel and MK-3475 for advanced non-small cell lung cancer (NSCLC)
Stages: III B, IV  CT.GOV ID: NCT02382406
Primary Investigator: Ryan Gentzler
CRC: Gracie Tubbs

Thoracic Oncology
16-18502 PHAR X396-CLI-101
Phase I/II, First-in-Human, Dose-Escalation Study of X-396 in Patients with Advanced Solid Tumors and Expansion Phase in Patients with ALK+ Non-Small Cell Lung Cancer
Stages: Not specified  CT.GOV ID: NCT01625234
Primary Investigator: Richard Hall
CRC: Karen Parks RN

All Studies Currently Open
Breast Oncology
00-8825 Other: Externally Peer-Reviewed KOMEN-FOUNDATION
Novel System for Dual Modality Tomographic Breast Imaging
Stages: Not specified  CT.GOV ID: Not specified
Primary Investigator: Mark Williams PhD
CRC: Joanne Gersbach

12-15885 UVA single-site BREAST43
Building a better model: a comprehensive breast cancer risk model incorporating breast density to stratify risk and apply resources
Stages: Not specified  CT.GOV ID: Not specified
Primary Investigator: Jennifer Harvey MD
CRC: Kathy Repich

Breast Oncology
13-16686 BREAST-IMAGING
Evaluation of Contrast Enhanced Mammography, Contrast Enhanced Breast Tomosynthesis, Breast Specific Gamma Imaging, and Gamma Emission Breast Tomosynthesis
Stages: Not specified  CT.GOV ID: Not specified
Primary Investigator: Mark Williams PhD
CRC: Joanne Gersbach

14-16965 Other: National NSABP-B-51
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Stages: II, III  CT.GOV ID: NCT01872975
Primary Investigator: Shayna Showalter MD
CRC: Katie Rea
Breast Oncology
14-16966 Other: National A011202
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (CT-3 N1) Who Have Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Stages: I; II; III CT.GOV ID: NCT01901094
Primary Investigator: Shayna Showalter MD
CRC: Katie Rea

14-17483 Other: National S1207
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating The Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk Hormone Receptor-Positive and Her2/Neu Negative Breast Cancer Patients
Stages: I; II; III CT.GOV ID: NCT01674140
Primary Investigator: Patrick Dillon MD
CRC: Lisa Malyn

15-17762 PHAR HER-NEU-VAX-2014-0443
Phase II Trial of Combination Immunotherapy with nelipepimut-S + GM-CSF (NeuVax) and Trastuzumab in high-risk HER2+ Breast Cancer Patients
Stages: I; II; III CT.GOV ID: NCT02297698
Primary Investigator: Patrick Dillon MD
CRC: Emily Allred

15-18004 UVA single-site BREAST-IORT-002
A Prospective Single-Arm Phase II Study To Investigate The Efficacy Of Single-Fraction Intraoperative Radiation Treatment Using A Multi-Lumen Balloon Applicator And In-Room CT Imaging For The Treatment Of Early-Stage Breast Cancer
Stages: II; I CT.GOV ID: NCT02400658
Primary Investigator: Shayna Showalter MD
CRC: Katie Rea

15-18072 Other: National E2112
A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Men and Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer
Stages: III; IV CT.GOV ID: NCT02145282
Primary Investigator: Christiana Brenin MD
CRC: Lisa Malyn

16-18436 PHAR SOPHIA
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Two Prior Anti-HER2 Therapies and Require Systemic Treatment
Stages: Not specified CT.GOV ID: Not specified
Primary Investigator: Christiana Brenin MD
CRC: Natalie Salsini

15-18525 Other: Externally Peer-Reviewed COH123
Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adult Females with Breast Cancer
Stages: I; II; III CT.GOV ID: Not specified
Primary Investigator: Erika Ramsdale
CRC: Natalie Salsini

Gastrointestinal Oncology
14-17434 PHAR ABI-007-PANC-003
A Phase 3, Multicenter, Open-Label, Randomized Study of nab®-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone As Adjuvant Therapy In Subjects With Surgically Resected Pancreatic Adenocarcinoma
Stages: I; II; III CT.GOV ID: NCT01964430
Primary Investigator: Osama Rahma
CRC: Julio Torres

15-17459 PHAR SONORHEOMETRY
Sonorheometry to predict thrombotic risk in patients with cancer
Stages: Not specified CT.GOV ID: Not specified
Primary Investigator: Hillary Maitland
CRC: Julio Torres

14-17546 PHAR EVOLUTION-STENT
Evaluation of the Effectiveness of Evolution® Biliary Stent System-Fully Covered
Stages: Not specified CT.GOV ID: NCT02104076
Primary Investigator: Andrew Wang
CRC: Sandra Oliphant RN, BSN, CCRC

Genitourinary Oncology
12-14266 UVA multi-site CARESS
Couples Arousal Relationship Satisfaction Survey
Stages: Not specified CT.GOV ID: Not specified
Primary Investigator: Tracey Krupski
CRC: Patricia Battle RN

13-16392 PHAR P10-3
A Registry of Sipuleucel-T Therapy in Men with Advanced Prostate Cancer
Stages: Not specified CT.GOV ID: Not specified
Primary Investigator: Tracey Krupski
CRC: Patricia Battle RN

For more information call or email Leticia Murray | 434.202.6025 | lm5us@virginia.edu
Genitourinary Oncology

13-16604 UVA multi-site HYPO-FX-UVA
Hypofractionated post-prostatectomy radiotherapy for prostate cancer to reduce toxicity and improve patient convenience: A Phase I/II trial
Stages: Any/all stages CT.GOV ID: NCT01868386
Primary Investigator: Timothy Showalter
CRC: Parchayi Dalal

13-16946 UVA single-site PROSTATE-SURVIVAL
Evaluation of Survival in Patients with Metastatic Prostate Cancer undergoing Treatment of the Primary Tumor
Stages: Not specified CT.GOV ID: NCT01982872
Primary Investigator: Stephen Culp
CRC: Elaine Woodson

13-17031 PHAR AGS-003-007
An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)
Stages: III; IV CT.GOV ID: NCT01856192
Primary Investigator: Tracey Krupski
CRC: Patricia Batlle RN

14-17079 Other: National RTOG0924
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Stages: I; II; III; IV CT.GOV ID: NCT01856192
Primary Investigator: Timothy Showalter
CRC: Parchayi Dalal

14-17456 UVA single-site PROSTATE-04
A pilot study to assess the combination of stereotactic body radiation therapy and CDX-1127 in modulating local and systemic T-cell responses against prostate cancer
Stages: Any/all stages CT.GOV ID: NCT02284971
Primary Investigator: James Larner MD
CRC: Kristy Scott

15-17902 Other: National A031201
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Stages: Not specified CT.GOV ID: NCT01949337
Primary Investigator: Robert Dreicer
CRC: Julio Torres

15-17959 Other: National S1314
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
Stages: Not specified CT.GOV ID: NCT02177695
Primary Investigator: Robert Dreicer
CRC: Julio Torres

15-18096 PHAR ASN001-101
A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion And Extension Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ASN001 In Subjects With Metastatic Progressive Castrate Resistant Prostate Cancer
Stages: Not specified CT.GOV ID: NCT02349139
Primary Investigator: Robert Dreicer
CRC: Buki Akinola

Genitourinary Oncology

15-18169 PHAR WQ29636
Stages: Not specified CT.GOV ID: NCT02450331
Primary Investigator: Robert Dreicer
CRC: Buki Akinola

Genitourinary Oncology

15-18175 PHAR GU115
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Stages: IV CT.GOV ID: NCT02407054
Primary Investigator: Robert Dreicer
CRC: Julio Torres

Gynecologic Oncology

08-13501 Other: National GOG-0213
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination With Bevacizumab (NSC #704865, IND #7921) Followed By Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Fallopian Tube and Peritoneal Primary Cancer
Stages: Not specified CT.GOV ID: NCT00565851
Primary Investigator: Susan Modesitt MD
CRC: Sanja Arapovic

10-14864 Other: National 9923
A Phase 1 Study of Carboplatin/Paclitaxel/CTEP-supplied Agent Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Containing, Fallopian Tube or Primary Peritoneal Cancer
Stages: II; III; IV CT.GOV ID: NCT00989651
Primary Investigator: Linda Duska MD
CRC: Timothy Howland

11-15391 UVA multi-site FRAILTY-ASSESSMENT
Frailty: An Outcome Predictor for Elderly Gynecologic Oncology Patients?
Stages: Not specified CT.GOV ID: NCT00989651
Primary Investigator: Leigh Cantrell MD
CRC: Timothy Howland

12-16153 UVA multi-site OVA-T-UVA
A Randomized Phase II Evaluation Of Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone In The Treatment Of Persistent Or Recurrent Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma
Stages: II CT.GOV ID: NCT01610206
Primary Investigator: Linda Duska MD
CRC: Sanja Arapovic
Gynecologic Oncology

12-1637 Other: National GOG225
Can Diet and Physical Activity Modulate Ovarian & Primary Peritoneal Cancer Progression Free Survival?
Stages: Not specified CT.GOV ID: Not specified
Primary Investigator: Susan Modesitt MD
CRC: Anne Gabel

12-1641 Other: National ANZGOG-0902-GOG-0274
A Phase III Trial of Adjuvant Chemotherapy as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The Outback Trial (ANZGOG 0902-GOG-0274/RTOG 1174)
Stages: I B; II; III B; IV A CT.GOV ID: NCT01414608
Primary Investigator: Susan Modesitt MD
CRC: Anne Gabel

14-16836 Non-UVA IUCRO-0383
Determining the Sensitivity of Sentinel Lymph Nodes Identified with Robotic Fluorescence Imaging for Detecting Metastatic Endometrial and Cervical Cancer.
Stages: I; I A; I B CT.GOV ID: NCT01673022
Primary Investigator: Leigh Cantrell MD
CRC: Timothy Howell

13-17040 PHAR ARRAY-162-311
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum
Stages: Not specified CT.GOV ID: NCT01849874
Primary Investigator: Leigh Cantrell MD
CRC: Sanja Arapovic

14-17366 UVA multi-site 17366
Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Stages: Not specified CT.GOV ID: NCT01666979
Primary Investigator: Linda Duska MD
CRC: Anne Gabel

14-17381 Other: National GOG-0286B
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (MSC#91485) versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Stages: Not specified CT.GOV ID: NCT02066587
Primary Investigator: Susan Modesitt MD
CRC: Anne Gabel

15-17723 Other: National GOG3005
A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stage III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Stages: III; IV CT.GOV ID: NCT02470585
Primary Investigator: Linda Duska MD
CRC: Anne Gabel

15-17782 UVA single-site ENDOMETRIAL-PATHOLOGY2
A Prospective evaluation of hormonal and glucose regulators in pre- and postmenopausal women with and without endometrial cancer undergoing hysterectomy
Stages: Not specified CT.GOV ID: Not specified
Primary Investigator: Susan Modesitt MD
CRC: Anne Gabel

Head & Neck Oncology

13-16376 UVA single-site SCCA-TORS-2012
A Single Arm Study of Efficacy and Functional Quality of Life in Patients Treated with Transoral Robotic Surgery for Oropharyngeal and Supraglottic Squamous Cell Carcinoma
Stages: I; II; III CT.GOV ID: NCT01819480
Primary Investigator: Mark Jameson MD, PhD
CRC: BJ Ferrebee Ghamandi

13-16544 UVA single-site TC-P2-CALCITRIOL
A Phase 2, placebo-controlled, randomized study to evaluate the effect of pre-operative vitamin D supplementation on hypocalcemia following total or near-total thyroidectomy
Stages: Any/all stages CT.GOV ID: NCT01868750
Primary Investigator: Linda Duska MD
CRC: Anne Gabel


**Head & Neck Oncology**

15-18172 PHAR MK3475-048  
A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) In First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma  
Stages: IV  CT.GOV ID: NCT02358031  
Primary Investigator: Elizabeth Gaughan  
CRC: Sarah Kelley

**Hematologic Malignancies**

12-16620 Other: National E1411  
Intergroup Randomized Phase II Four Arm Study In Patients >= 60 With Previously Untreated Mantle Cell Lymphoma  
Stages: Any/all stages  CT.GOV ID: NCT01415752  
Primary Investigator: Michael Williams MD  
CRC: Andrea Ruhsam BS, BA, CCRC

13-16706 UVA single-site BRETTCELLCYTOTOXICITY  
Effect of targeted therapies on leukemia and lymphoma cell cytotoxicity and signal transduction - Brett Cell Cytotoxicity  
Stages: Not specified  CT.GOV ID: Not specified  
Primary Investigator: Craig Portell  
CRC: Kim Underwood BS, CCRC

14-16770 PHAR SGN35-014  
A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas  
Stages: Any/all stages  CT.GOV ID: NCT01777152  
Primary Investigator: Michael Douvas MD  
CRC: Kim Underwood BS, CCRC

14-17063 Other: National E1412  
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vinchristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma  
Stages: Not specified  CT.GOV ID: NCT01856192  
Primary Investigator: Michael Williams MD  
CRC: Andrea Ruhsam BS, BA, CCRC

14-17193 Other: National PRE0401  
Phase II Randomized Trial Comparing GA101 (Obinutuzumab) and Rituximab in Patients with Previously Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma  
Stages: III; IV  CT.GOV ID: NCT01889797  
Primary Investigator: Craig Portell  
CRC: Andrea Ruhsam BS, BA, CCRC

15-17748 PHAR BO29337  
A Phase II, Open-Label Study Evaluating the Safety and Efficacy of GDC-0199 (ABT-199) Plus Bendamustine Plus Rituximab (BR) in Comparison with BR Alone or GDC-0199 Plus Rituximab (R) in Patients with Relapsed and Refractory Follicular Non-Hodgkin’s Lymphoma  
Stages: Not specified  CT.GOV ID: NCT02187861  
Primary Investigator: Craig Portell  
CRC: Kim Underwood BS, CCRC

15-17983 UVA multi-site ABT199-MCL-UVA  
Multi-institution Phase IIb study of ibrutinib with ABT-199 in relapsed/refractory mantle cell lymphoma  
Stages: Any/all stages  CT.GOV ID: NCT02419560  
Primary Investigator: Craig Portell  
CRC: Kim Underwood BS, CCRC

**Melanoma**

13-16223 PHAR 103A-301  
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence  
Stages: II B; II C; III  CT.GOV ID: NCT01546571  
Primary Investigator: Craig Slingluff MD  
CRC: Emily Allred

13-16347 PHAR LUD2012-004  
Phase I Study of NY-ESO-1 Vaccine in Combination with Ipilimumab in Patients with Unresectable or Metastatic Melanoma, for whom Treatment with Ipilimumab is Indicated  
Stages: Not specified  CT.GOV ID: NCT01810016  
Primary Investigator: Craig Slingluff MD  
CRC: Emily Allred

14-16952 Other: Externally Peer-Reviewed CITN-04  
A Phase II Pilot Trial of an Indoleamine2,3, dioxygenase-1 (IDO1) Inhibitor(INCB024360) Plus a Multipeptide Melanoma Vaccine (MELITAC 12.1) in Patients with Advanced Melanoma  
Stages: III; IV  CT.GOV ID: NCT01961115  
Primary Investigator: Craig Slingluff MD  
CRC: Emily Allred

15-17780 Other: Externally Peer-Reviewed MEL-62  
A Phase III trial to evaluate the safety, immunogenicity, and clinical activity of a helper peptide vaccine plus CTLA-4 blockade in Advanced Melanoma (MEL62; 6PAC)  
Stages: III B; III C; IV  CT.GOV ID: NCT02385669  
Primary Investigator: Craig Slingluff MD  
CRC: Emily Allred

15-17860 Other: Externally Peer-Reviewed MEL-63  
A trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus novel adjuvant combinations (MEL63)  
Stages: II; III; IV  CT.GOV ID: NCT02425306  
Primary Investigator: Craig Slingluff MD  
CRC: Emily Allred

15-18174 Other: Externally Peer-Reviewed MEL-64  
A trial to evaluate the safety, immunogenicity, and clinical activity of a helper peptide vaccine plus PD-1 blockade  
Stages: II B; III C, IV  CT.GOV ID: NCT02515227  
Primary Investigator: Craig Slingluff MD  
CRC: Emily Allred

16-18569 Other: National EA6141  
Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma  
Stages: III; IV  CT.GOV ID: NCT02339571  
Primary Investigator: Elizabeth Gaughan  
CRC: Emily Allred
**Pediatric Oncology**

09-14665 Other: National E3F05  
**Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas**  
Stages: Not specified  
Primary Investigator: David Schiff MD  
CRC: Johanna Loomba BS

13-16463 Other: National N1174  
**Phase I/Comparative Randomized Phase II Trial of TRC105 plus Bevacizumab Versus Bevacizumab in Bevacizumab-Naïve Patients with Recurrent Glioblastoma Multiforme**  
Stages: Not specified  
Primary Investigator: David Schiff MD  
CRC: Cara Hanby

14-17161 MC1281  
**Phase I Trial of Pomalidomide for Patients with Relapsed/Refractory Primary CNS Lymphoma and Patients with Newly Diagnosed or Relapsed/Refractory Primary Vitreoretinal Lymphoma**  
Stages: Not specified  
Primary Investigator: David Schiff MD  
CRC: Cara Hanby

14-17466 PHAR STML-701-0114  
**A phase 1/2 study of SL-701, a subcutaneously injected multivalent glioma-associated antigen vaccine, in adult patients with recurrent glioblastoma multiforme.**  
Stages: Not specified  
Primary Investigator: David Schiff MD  
CRC: Heather Tribout

15-18395 Other: National A071401  
**Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations**  
Stages: Not specified  
Primary Investigator: David Schiff MD  
CRC: Cara Hanby

14-18471 PHAR TGS11-15-01  
**A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma**  
Stages: Not specified  
Primary Investigator: David Schiff MD  
CRC: Cara Hanby

**Pediatric Oncology**

09-8318 Other: National D9002  
**A Group-Wide Protocol for Collecting and Banking Pediatric Cancer Research Specimens. an Intergroup Rhabdomyosarcoma Study Group Protocol**  
Stages: Not specified  
Primary Investigator: Kim Dunsmore MD  
CRC: Candace Hudspeth BA, CCRC

01-9302 Other: National ANBL00B1  
**Neuroblastoma Biology Studies: a Children's Oncology Group Study**  
Stages: Not specified  
Primary Investigator: Kim Dunsmore MD  
CRC: Candace Hudspeth BA, CCRC

08-13669 Other: National AREN03B2  
**Renal Tumors Classification, Biology and Banking Study**  
Stages: Not specified  
Primary Investigator: Kim Dunsmore MD  
CRC: Candace Hudspeth BA, CCRC

10-14764 Other: National AHEP0731  
**Treatment of Children With All Stages of Hepatoblastoma: A Groupwide Phase III Study**  
Stages: I; II; III; IV  
Primary Investigator: Kim Dunsmore MD  
CRC: Candace Hudspeth BA, CCRC

11-15479 Other: National AALL08B1  
**Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)**  
Stages: Any/all stages  
Primary Investigator: Kim Dunsmore MD  
CRC: Candace Hudspeth BA, CCRC

11-15583 Other: National AALL0932  
**Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL): A Groupwide Phase III Study**  
Stages: Not specified  
Primary Investigator: Kim Dunsmore MD  
CRC: Candace Hudspeth BA, CCRC

11-15896 Other: National AAML08B1  
**Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS)**  
Stages: Not specified  
Primary Investigator: Kim Dunsmore MD  
CRC: Candace Hudspeth BA, CCRC

13-15897 Other: National ACCL0933  
**A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)**  
Stages: Any/all stages  
Primary Investigator: Kim Dunsmore MD  
CRC: Candace Hudspeth BA, CCRC

12-16462 Other: National AALL1131  
**A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum**  
Stages: Any/all stages  
Primary Investigator: Kim Dunsmore MD  
CRC: Candace Hudspeth BA, CCRC
Pediatric Oncology

12-16648 Other: National ALTE07C1
Neuropsychological, Social, Emotional and Behavioral Outcomes in Children with Cancer
Stages: Any/all ages  CT.GOV ID: NCT00772200
Primary Investigator: Colleen Druzgal
CRC: Jessica Pritchard

13-16951 Other: National ACNS1123
Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)
Stages: Not specified  CT.GOV ID: NCT01602666
Primary Investigator: Colleen Druzgal
CRC: Jessica Pritchard

14-17165 UVA single-site PEDSSOLIDTUMORDATABASE
Pediatric Relapsed Solid Tumor Database
Stages: Not specified  CT.GOV ID: Not specified
Primary Investigator: Aaron Quinlan
CRC: Candace Hudspeth BA, CCRC

15-17264 Other: National ACCL0922
A Phase II Placebo-Controlled Trial of Modafinil to Improve Neuropsychometric Deficits in Children Treated for a Primary Brain Tumor
Stages: Any/all ages  CT.GOV ID: NCT01381718
Primary Investigator: Colleen Druzgal
CRC: Jessica Pritchard

16-17588 UVA multi-site UVA-GEN001
A Randomized, Placebo-Controlled Pilot Study of Genistein Supplementation in Pediatric Cancer Patients Receiving Myelosuppressive Chemotherapy
Stages: Any/all ages  CT.GOV ID: NCT02624388
Primary Investigator: William Petersen MD
CRC: Jessica Pritchard

16-17715 Other: National ARST1321
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase III/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)
Stages: Any/all stages  CT.GOV ID: NCT02180867
Primary Investigator: William Petersen MD
CRC: Candace Hudspeth BA, CCRC

15-17717 Other: National ANBL1232
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma
Stages: Not specified  CT.GOV ID: NCT02176967
Primary Investigator: Kim Dunsmore MD
CRC: Candace Hudspeth BA, CCRC

16-18713 Other: National AOST1321
AOST1321: Phase 2 Study of Denosumab (IND# 127430, NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma
Stages: Not specified  CT.GOV ID: NCT02470091
Primary Investigator: William Petersen MD
CRC: Jessica Pritchard

Thoracic Oncology

12-16005 Other: Externally Peer-Reviewed LCIS-R01
A Decision Aid with HRQL Assessment to Reduce Costs in the Treatment of NSCLC (LCIS-R01)
Stages: III B; IV  CT.GOV ID: Not specified
Primary Investigator: Patricia Hollen PhD, RN
CRC: Bethany Coyle

14-17719 Other: National A151216
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Stages: Not specified  CT.GOV ID: NCT02194738
Primary Investigator: Richard Hall
CRC: Galina Diakova

14-17720 Other: National A081105
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Stages: I B; II; III A  CT.GOV ID: NCT02193282
Primary Investigator: Richard Hall
CRC: Galina Diakova

14-17721 Other: National E4512
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Stages: I B; II; III A  CT.GOV ID: NCT02201992
Primary Investigator: Richard Hall
CRC: Galina Diakova

15-17857 Other: National S1400
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer
Stages: Not specified  CT.GOV ID: NCT02154490
Primary Investigator: Ryan Gentzler
CRC: Galina Diakova

15-17921 PHAR M14-360
A Phase 1 Dose Escalation and Phase 2 Randomized, Placebo-Controlled Study of the Efficacy and Tolerability of Veliparib in Combination with Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects with Stage III Non-Small Cell Lung Cancer (NSCLC)
Stages: III  CT.GOV ID: NCT02412371
Primary Investigator: James Lerner MD
CRC: Parchayi Dalal

15-18173 PHAR LUN288
A Phase II Study of the Combination of LY302414 and Necitumumab after First-Line Chemotherapy for Metastatic Squamous Non-small Cell Carcinoma of the Lung
Stages: Not specified  CT.GOV ID: NCT02443337
Primary Investigator: Richard Hall
CRC: Galina Diakova

16-18368 Non-UVA LUN13-175
Phase I/II study of carboplatin/nab-paclitaxel and MK-3475 for advanced non-small cell lung cancer (NSCLC)
Stages: III B; IV  CT.GOV ID: NCT02362406
Primary Investigator: Ryan Gentzler
CRC: Gracie Tubbs

For more information call or email Leticia Murray | 434.202.6025 | lm5us@virginia.edu
15-18371 PHAR CO-1686-020
TIGER-3: A Phase 3, Open-label, Multicenter, Randomized Study of Oral Nocleitbin (CO-1686) Monotherapy Versus Single-agent Cytotoxic Chemotherapy in Patients with Mutant EGFR Non-small Cell Lung Cancer (NSCLC) after Failure of at Least 1 Previous EGFR-directed Tyrosine Kinase Inhibitor (TKI) and Platinum-doublet Chemotherapy
Stages: Any/all stages  CT.GOV ID: NCT02322281
Primary Investigator: Richard Hall
CRC: Gracie Tubbs

16-18502 PHAR X396-CLI-101
Phase II/III, First-in-Human, Dose-Escalation Study of X-396 in Patients with Advanced Solid Tumors and Expansion Phase in Patients with ALK+ Non-Small Cell Lung Cancer
Stages: Not specified  CT.GOV ID: NCT01625234
Primary Investigator: Richard Hall
CRC: Karen Parks RN

Transplant
14-15670 Non-UVA 10-CBA
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications
Stages: Any/all stages  CT.GOV ID: NCT01351545
Primary Investigator: Tamila Kindwall-Keller DO
CRC: Andrea Ruhsam BS, BA, CCRC

12-16168 PHAR 6637-01
A multicenter safety study of unlicensed, investigational cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult patients.
Stages: Not specified  CT.GOV ID: NCT01656603
Primary Investigator: Tamila Kindwall-Keller DO
CRC: Andrea Ruhsam BS, BA, CCRC

12-16461 PHAR 2006-05
Defibrotide for Patients with Hepatic Veno-Occlusive Disease (VOD): A Treatment IND Study (Under CFR 312.34)
Stages: III  CT.GOV ID: NCT00828498
Primary Investigator: Tamila Kindwall-Keller DO
CRC: Andrea Ruhsam BS, BA, CCRC

14-17215 UVA single-site MM-CD34
A Prospective Observational Study of the Association Between CD34+ Cell-Dose Infused in Autologous Stem Cell Transplantation and Engraftment in Multiple Myeloma Patients
Stages: Not specified  CT.GOV ID: Not specified
Primary Investigator: Tamila Kindwall-Keller DO
CRC: Adam Schettler

15-17732 PHAR CELLDEX301-03
A Pilot Study of CDX-301 (rhuFlt3L) with or without Plerixafor for the Mobilization and Transplantation of Allogeneic Blood Cell Grafts in HLA-Matched Donor/Recipient Sibling Pairs
Stages: Any/all stages  CT.GOV ID: NCT02200380
Primary Investigator: Tamila Kindwall-Keller DO
CRC: Andrea Ruhsam BS, BA, CCRC

Other Oncology Trials
13-16964 UVA single-site STAT-RT-1/2
A Phase III Single Arm Prospective Single Fraction Real-time Stereotactic Body Radiation Therapy Dose Escalation Trial of Rapid Helical TomoTherapy-based Radiation Therapy for Patients with Painful Osseous Metastatic Disease
Stages: Any/all stages  CT.GOV ID: NCT02145286
Primary Investigator: Paul Read MD
CRC: Parchayi Dalal

15-17576 UVA single-site AG-CDD
Alanyl-Glutamine Supplementation of Standard Treatment for C. Difficile Infection: A Randomized, Double-Blind, Placebo-Controlled Trial
Stages: Any/all stages  CT.GOV ID: NCT02053350
Primary Investigator: Cirle Warren
CRC: Cirle Warren

15-18445 ORIEN
Partners in Discovery for Total Cancer Care at UVA
Stages: Any/all stages  CT.GOV ID: Not specified
Primary Investigator: Christopher Moskaluk PhD
CRC: Jake Boyd

12-2010017400 Other: Externally Peer-Reviewed CANCER-Cancer Patient Navigation: Training and Intervention Implementation and Evaluation
Stages: Not specified  CT.GOV ID: Not specified
Primary Investigator: Randy Jones PhD, RN
CRC: Randy Jones PhD, RN

15-2015004500 UVA single-site P3P-II
Personal Patient Profile-Prostate II (P3P-II)
Stages: Not specified  CT.GOV ID: Not specified
Primary Investigator: Randy Jones PhD, RN
CRC: Elaine Woodson

15-2011017200 UVA single-site P3P-II
Evaluation of Factors Associated with Participation in Cancer Clinical Trials
Stages: Any/all stages  CT.GOV ID: Not specified
Primary Investigator: Randy Jones PhD, RN
CRC: Leticia Murray
<table>
<thead>
<tr>
<th>Name</th>
<th>Phone</th>
<th>Email</th>
<th>Name</th>
<th>Phone</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buki Akinola</td>
<td>434-297-7827</td>
<td><a href="mailto:aa5rh@virginia.edu">aa5rh@virginia.edu</a></td>
<td>Andrea Ruhsam</td>
<td>434-297-7812</td>
<td><a href="mailto:ar8q@virginia.edu">ar8q@virginia.edu</a></td>
</tr>
<tr>
<td>Emily Allred</td>
<td>434-982-1902</td>
<td><a href="mailto:eh4m@virginia.edu">eh4m@virginia.edu</a></td>
<td>Natalie Salsini</td>
<td>434-297-7782</td>
<td><a href="mailto:ns9sr@virginia.edu">ns9sr@virginia.edu</a></td>
</tr>
<tr>
<td>Sanja Arapovic</td>
<td>434-924-2745</td>
<td><a href="mailto:su2x@virginia.edu">su2x@virginia.edu</a></td>
<td>Adam Schettler</td>
<td>434-297-7783</td>
<td><a href="mailto:ajs6qs@virginia.edu">ajs6qs@virginia.edu</a></td>
</tr>
<tr>
<td>Patricia Battle</td>
<td>434-924-5649</td>
<td><a href="mailto:pya@virginia.edu">pya@virginia.edu</a></td>
<td>Annika Shuali</td>
<td>434-243-7242</td>
<td><a href="mailto:ah2ze@virginia.edu">ah2ze@virginia.edu</a></td>
</tr>
<tr>
<td>Cricket Birk</td>
<td>434-924-2283</td>
<td><a href="mailto:meb2w@virginia.edu">meb2w@virginia.edu</a></td>
<td>Cody Slicker</td>
<td>434-924-6055</td>
<td><a href="mailto:CS6XJ@virginia.edu">CS6XJ@virginia.edu</a></td>
</tr>
<tr>
<td>Kirsten Bjorson</td>
<td>434-243-3920</td>
<td><a href="mailto:kb8wjf@virginia.edu">kb8wjf@virginia.edu</a></td>
<td>Aimee Strong</td>
<td>434-243-0416</td>
<td><a href="mailto:alc8p@virginia.edu">alc8p@virginia.edu</a></td>
</tr>
<tr>
<td>Kathy Bohorfhous</td>
<td>434-243-6152</td>
<td><a href="mailto:kec@virginia.edu">kec@virginia.edu</a></td>
<td>Julio Torres</td>
<td>434-924-9199</td>
<td><a href="mailto:j4hs@virginia.edu">j4hs@virginia.edu</a></td>
</tr>
<tr>
<td>Jake Boyd</td>
<td>434-243-3983</td>
<td><a href="mailto:lib2wnr@virginia.edu">lib2wnr@virginia.edu</a></td>
<td>Gracie Tubbs</td>
<td>434-297-7784</td>
<td><a href="mailto:mg4rn@virginia.edu">mg4rn@virginia.edu</a></td>
</tr>
<tr>
<td>Kim Bullock</td>
<td>434-924-0180</td>
<td><a href="mailto:kb9dd@virginia.edu">kb9dd@virginia.edu</a></td>
<td>Beverly Turner</td>
<td>434-982-3948</td>
<td><a href="mailto:BT2H@virginia.edu">BT2H@virginia.edu</a></td>
</tr>
<tr>
<td>Sandra Burks</td>
<td>434-243-0315</td>
<td><a href="mailto:sbg2c@virginia.edu">sbg2c@virginia.edu</a></td>
<td>Kim Underwood</td>
<td>434-982-3947</td>
<td><a href="mailto:km3q@virginia.edu">km3q@virginia.edu</a></td>
</tr>
<tr>
<td>Amy Camblos</td>
<td>434-243-1927</td>
<td><a href="mailto:ak04c@virginia.edu">ak04c@virginia.edu</a></td>
<td>Lisa Williams</td>
<td>434-243-0315</td>
<td><a href="mailto:lw3n@virginia.edu">lw3n@virginia.edu</a></td>
</tr>
<tr>
<td>Alex Carney</td>
<td>434-982-1901</td>
<td><a href="mailto:alc6a2@virginia.edu">alc6a2@virginia.edu</a></td>
<td>Stacey Williams</td>
<td>434-243-8588</td>
<td><a href="mailto:scw6n@virginia.edu">scw6n@virginia.edu</a></td>
</tr>
<tr>
<td>Gloria Carter</td>
<td>434-924-0597</td>
<td><a href="mailto:gcb7qg@virginia.edu">gcb7qg@virginia.edu</a></td>
<td>Elaine Woodson</td>
<td>434-982-3704</td>
<td><a href="mailto:mew3u@virginia.edu">mew3u@virginia.edu</a></td>
</tr>
<tr>
<td>David Cohen</td>
<td>434-243-0315</td>
<td><a href="mailto:dac7ba@virginia.edu">dac7ba@virginia.edu</a></td>
<td>Jessica Zareno</td>
<td>434-982-1901</td>
<td><a href="mailto:jhz4f@virginia.edu">jhz4f@virginia.edu</a></td>
</tr>
<tr>
<td>Bethany Coyne</td>
<td>434-924-5686</td>
<td><a href="mailto:bmc8b@virginia.edu">bmc8b@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parchayi Dalal</td>
<td>434-243-7231</td>
<td><a href="mailto:pd9dj@virginia.edu">pd9dj@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Holly Davis</td>
<td>434-243-7064</td>
<td><a href="mailto:HAW5D@virginia.edu">HAW5D@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melissa Dean-McKinney</td>
<td>434-243-2649</td>
<td><a href="mailto:mdd3a@virginia.edu">mdd3a@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Galina Diakova</td>
<td>434-924-5990</td>
<td><a href="mailto:GBDA4G@virginia.edu">GBDA4G@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elaine Dube</td>
<td>434-982-5168</td>
<td><a href="mailto:ed7y@virginia.edu">ed7y@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lori Elder</td>
<td>434-924-8570</td>
<td><a href="mailto:lje5u@virginia.edu">lje5u@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jeannine Erickson</td>
<td>434-924-0300</td>
<td><a href="mailto:jme3a@virginia.edu">jme3a@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BJ Ferrebee Ghamandi</td>
<td>434-243-1558</td>
<td><a href="mailto:bjf8@virginia.edu">bjf8@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cynthia Fischer</td>
<td>434-243-0910</td>
<td><a href="mailto:crb3y@virginia.edu">crb3y@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anne Gabel</td>
<td>434-982-6657</td>
<td><a href="mailto:am7bd@virginia.edu">am7bd@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jane Gildersleeve</td>
<td>434-243-1958</td>
<td><a href="mailto:JLG2G@virginia.edu">JLG2G@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patty Goodale Judy</td>
<td>434-924-9400</td>
<td><a href="mailto:pjt7e@virginia.edu">pjt7e@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cara Hanby</td>
<td>434-243-9900</td>
<td><a href="mailto:CLH5KE@virginia.edu">CLH5KE@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amy Harrigan</td>
<td>434-982-6532</td>
<td><a href="mailto:acm6a@virginia.edu">acm6a@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Joanne Harris</td>
<td>434-924-5254</td>
<td><a href="mailto:jrh3zt@virginia.edu">jrh3zt@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Michelle Haughey</td>
<td>434-924-9199</td>
<td><a href="mailto:mh7re@virginia.edu">mh7re@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Susan Houckens</td>
<td>434-982-6582</td>
<td><a href="mailto:sw6h4v@virginia.edu">sw6h4v@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Timothy Howland</td>
<td>434-243-0032</td>
<td><a href="mailto:th3vn@virginia.edu">th3vn@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Candace Hudspeth</td>
<td>434-982-1091</td>
<td><a href="mailto:ckh3k@virginia.edu">ckh3k@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sarah Kelley</td>
<td>434-982-6584</td>
<td><a href="mailto:SLK6VU@virginia.edu">SLK6VU@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brigitte Kelly</td>
<td>434-297-7136</td>
<td><a href="mailto:bjk3c@virginia.edu">bjk3c@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Michael Kidd</td>
<td>434-924-9446</td>
<td><a href="mailto:mwk2c@virginia.edu">mwk2c@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Royanne Koogler</td>
<td>434-924-9496</td>
<td><a href="mailto:rb8y@virginia.edu">rb8y@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amy Lankford</td>
<td>434-982-6271</td>
<td><a href="mailto:ARL2B@virginia.edu">ARL2B@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heather Lothamer</td>
<td>434-924-9924</td>
<td><a href="mailto:htf5y@virginia.edu">htf5y@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lisa Malyn</td>
<td>434-243-0425</td>
<td><a href="mailto:lal7as@virginia.edu">lal7as@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Karen McDonnell</td>
<td>703-967-6904</td>
<td><a href="mailto:kkm7p@virginia.edu">kkm7p@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Charles McMillian</td>
<td>434-243-6575</td>
<td><a href="mailto:crm3h@virginia.edu">crm3h@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leticia Murray</td>
<td>434-243-6303</td>
<td><a href="mailto:lm5us@virginia.edu">lm5us@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Karen Parks</td>
<td>434-924-6055</td>
<td><a href="mailto:knp@virginia.edu">knp@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jennifer Phillips</td>
<td>434-243-0315</td>
<td><a href="mailto:jvp8a@virginia.edu">jvp8a@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jessica Pritchard</td>
<td>434-924-0370</td>
<td><a href="mailto:jep4n@virginia.edu">jep4n@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goga Radakovic</td>
<td>434-982-4213</td>
<td><a href="mailto:qz2p@virginia.edu">qz2p@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Catherine Ratliff</td>
<td>434-982-2922</td>
<td><a href="mailto:crr9m@virginia.edu">crr9m@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Katie Rea</td>
<td>434-243-3015</td>
<td><a href="mailto:kaw3j@virginia.edu">kaw3j@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kathy Repich</td>
<td>434-243-4540</td>
<td><a href="mailto:klr3b@virginia.edu">klr3b@virginia.edu</a></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>